Pfizer (NYSE:PFE - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25, Zacks reports. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 earnings per share. Pfizer updated its FY 2025 guidance to 2.800-3.000 EPS.
Pfizer Trading Up 3.6 %
Shares of PFE stock traded up $0.84 during mid-day trading on Tuesday, hitting $23.89. The company's stock had a trading volume of 42,538,054 shares, compared to its average volume of 40,609,900. The company has a market cap of $135.48 billion, a PE ratio of 16.95, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company's fifty day simple moving average is $24.52 and its 200-day simple moving average is $25.88. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.20%. Pfizer's dividend payout ratio (DPR) is currently 121.99%.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group reduced their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.57.
Check Out Our Latest Stock Analysis on Pfizer
Insider Activity at Pfizer
In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Pfizer
An institutional investor recently raised its position in Pfizer stock. Brighton Jones LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1,282.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 666,318 shares of the biopharmaceutical company's stock after buying an additional 618,117 shares during the period. Brighton Jones LLC's holdings in Pfizer were worth $17,677,000 at the end of the most recent quarter. 68.36% of the stock is owned by institutional investors and hedge funds.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
